In2CoP 2020 - International Conference on Co-Creation Processes in Higher Education 2020: book of abstracts

A Cocriação e a Inovação no Ensino Superior representam um dos principais compromissos do Instituto Politécnico de Bragança (IPB), cuja atividade formativa e de investigação se orienta, de forma sinérgica, para a cooperação com as empresas e instituições da região. O IPB pretende contribuir, de forma ativa, para uma economia regional baseada no conhecimento e com uma forte articulação internacional. Nesta esteira, teve lugar, na cidade de Bragança, nos dias 29 a 30 de janeiro de 2020, a Conferência Internacional em Processos de Cocriação no Ensino Superior (In2CoP). Privilegiamos um espaço de reflexão de processos e de partilha de resultados de ecossistemas de cocriação, visando o desenvolvimento de uma comunidade de aprendizagem integradora, interdisciplinar e multicultural. Ao longo dos três dias da conferência, mais de 150 conferencistas, nacionais e estrangeiros, participaram, ativamente, nas diversas atividades propostas: uma sessão plenária com seis intervenções, quatro workshops e uma sessão pitch com a apresentação de trinta e seis projetos de inovação e cocriação. Com um espírito inovador, as atividades decorreram no campus do IPB e em espaços emblemáticos da cidade de Bragança, designadamente: Centro de Arte Contemporânea Graças Morais, Centro de Fotografia Georges Dussaud e Centro de Ciência Viva. Foi ainda realizada uma visita social ao Museu do Côa em Vila Nova de Foz Côa.Co-creation and Innovation in Higher Education represents one of the main commitments of the Polytechnic Institute of Bragança (IPB), whose training and research activity is synergistically oriented towards cooperation with companies and institutions in the region. The IPB intends to contribute actively to a regional economy based on knowledge and with a strong international articulation. In this context, the International Conference on Co-Creation Processes in Higher Education (In2CoP) took place in the city of Bragança, on January 29-30, 2020. We privilege a space for reflection of processes and sharing of results from co-creation ecosystems, aiming at the development of an integrative, interdisciplinary, and multicultural learning community. Over the three days of the conference, more than 150 national and foreign conferencists actively participated in the various activities proposed: a plenary session with six interventions, four workshops, and a pitch session with the presentation of thirty-six innovation and co-creation projects. With an innovative spirit, the activities took place in IPB's campus and in emblematic spaces in the city of Bragança, namely: Centro de Arte Contemporânea Graças Morais, Centro de Fotografia Georges Dussaud and Centro de Ciência Viva. A social visit was also made to the Côa Museum in Vila Nova de Foz Côa.info:eu-repo/semantics/publishedVersio

A Primeira Guerra Mundial : na Batalha de La Lys

O livro presentemente disponibilizado em formato e-book, por opção dos editores, constituí o resultado dos trabalhos de autor apresentados e desenvolvidos no âmbito do Congresso Internacional sobre a Primeira Guerra Mundial. No centenário da Batalha de la Lys que reuniu, nas instalações da Faculdade de Ciências Humanas e Sociais da Universidade Fernando Pessoa, nos passados dias 9 a 11 de abril de 2018, mais de duas dezenas de investigadores nacionais e estrangeiros com o intuito de proceder a uma análise multidisciplinar dos motivos, implicações, ocorrências e análises de um dos maiores acontecimentos bélicos da primeira metade do século XX. O congresso foi desenvolvido em associação com o Instituto da Defesa Nacional. A estrutura de apresentação dos textos obedece a uma subdivisão orgânica e temática, partindo de unidades temáticas de âmbito geral e problematizante para unidades temáticas específicas relacionadas, mormente com o contexto, o âmbito e as dimensões da participação portuguesa na Batalha de La Lys, estabelecendo uma relação de complementaridade entre ambas. Por conseguinte, a ordem de apresentação principia com um I capítulo intitulado “A problematização da Primeira Grande Guerra” e um II capítulo, especificamente dedicado à participação de “Portugal na Guerra - A Batalha de La Lys”. De igual modo, no III capítulo, intitulado “A guerra nas colónias” inserem-se todos os trabalhos que abordam, nomeadamente, a projeção do conflito nos domínios africanos portugueses, com destaque para a questão esclavagista e as ameaças anglófonas e germânicas, o papel de defesa da armada portuguesa em Cabo Verde, e, finalmente, a intimidação alemã na região de Tanganica (África Oriental). O IV capítulo é inteiramente dedicado à historiografia da guerra, incluindo estudos sobre a construção das imagens da participação de Portugal no conflito, as mudanças concetuais e as direções investigativas do discurso historiográfico, ao longo do século XX, e por último, as imagens da guerra na imprensa portuguesa. No V capítulo inserem-se os posters apresentados a congresso, abordando respetivamente o papel da Cruz Vermelha e o impacto da Primeira Guerra Mundial na cidade de Porto. Para fechar, no último capítulo (VI), foram reunidos todos os trabalhos que abordam problemáticas diversas relacionadas com o fenómeno guerra, mas que se encontram de algum modo mais distanciadas do núcleo temático principal do livro.info:eu-repo/semantics/publishedVersio

A Primeira Guerra Mundial : na Batalha de La Lys

O livro presentemente disponibilizado em formato e-book, por opção dos editores, constituí o resultado dos trabalhos de autor apresentados e desenvolvidos no âmbito do Congresso Internacional sobre a Primeira Guerra Mundial. No centenário da Batalha de la Lys que reuniu, nas instalações da Faculdade de Ciências Humanas e Sociais da Universidade Fernando Pessoa, nos passados dias 9 a 11 de abril de 2018, mais de duas dezenas de investigadores nacionais e estrangeiros com o intuito de proceder a uma análise multidisciplinar dos motivos, implicações, ocorrências e análises de um dos maiores acontecimentos bélicos da primeira metade do século XX. O congresso foi desenvolvido em associação com o Instituto da Defesa Nacional. A estrutura de apresentação dos textos obedece a uma subdivisão orgânica e temática, partindo de unidades temáticas de âmbito geral e problematizante para unidades temáticas específicas relacionadas, mormente com o contexto, o âmbito e as dimensões da participação portuguesa na Batalha de La Lys, estabelecendo uma relação de complementaridade entre ambas. Por conseguinte, a ordem de apresentação principia com um I capítulo intitulado “A problematização da Primeira Grande Guerra” e um II capítulo, especificamente dedicado à participação de “Portugal na Guerra - A Batalha de La Lys”. De igual modo, no III capítulo, intitulado “A guerra nas colónias” inserem-se todos os trabalhos que abordam, nomeadamente, a projeção do conflito nos domínios africanos portugueses, com destaque para a questão esclavagista e as ameaças anglófonas e germânicas, o papel de defesa da armada portuguesa em Cabo Verde, e, finalmente, a intimidação alemã na região de Tanganica (África Oriental). O IV capítulo é inteiramente dedicado à historiografia da guerra, incluindo estudos sobre a construção das imagens da participação de Portugal no conflito, as mudanças concetuais e as direções investigativas do discurso historiográfico, ao longo do século XX, e por último, as imagens da guerra na imprensa portuguesa. No V capítulo inserem-se os posters apresentados a congresso, abordando respetivamente o papel da Cruz Vermelha e o impacto da Primeira Guerra Mundial na cidade de Porto. Para fechar, no último capítulo (VI), foram reunidos todos os trabalhos que abordam problemáticas diversas relacionadas com o fenómeno guerra, mas que se encontram de algum modo mais distanciadas do núcleo temático principal do livro.info:eu-repo/semantics/publishedVersio

Is the inflammasome a potential therapeutic target in renal disease?

The inflammasome is a large, multiprotein complex that drives proinflammatory cytokine production in response to infection and tissue injury. Pattern recognition receptors that are either membrane bound or cytoplasmic trigger inflammasome assembly. These receptors sense danger signals including damage-associated molecular patterns and pathogen-associated molecular patterns (DAMPS and PAMPS respectively). The best-characterized inflammasome is the NLRP3 inflammasome. On assembly of the NLRP3 inflammasome, post-translational processing and secretion of pro-inflammatory cytokines IL-1β and IL-18 occurs; in addition, cell death may be mediated via caspase-1. Intrinsic renal cells express components of the inflammasome pathway. This is most prominent in tubular epithelial cells and, to a lesser degree, in glomeruli. Several primary renal diseases and systemic diseases affecting the kidney are associated with NLRP3 inflammasome/IL-1β/IL-18 axis activation. Most of the disorders studied have been acute inflammatory diseases. The disease spectrum includes ureteric obstruction, ischaemia reperfusion injury, glomerulonephritis, sepsis, hypoxia, glycerol-induced renal failure, and crystal nephropathy. In addition to mediating renal disease, the IL-1/ IL-18 axis may also be responsible for development of CKD itself and its related complications, including vascular calcification and sepsis. Experimental models using genetic deletions and/or receptor antagonists/antiserum against the NLRP3 inflammasome pathway have shown decreased severity of disease. As such, the inflammasome is an attractive potential therapeutic target in a variety of renal diseases

2 nd Brazilian Consensus on Chagas Disease, 2015

Abstract Chagas disease is a neglected chronic condition with a high burden of morbidity and mortality. It has considerable psychological, social, and economic impacts. The disease represents a significant public health issue in Brazil, with different regional patterns. This document presents the evidence that resulted in the Brazilian Consensus on Chagas Disease. The objective was to review and standardize strategies for diagnosis, treatment, prevention, and control of Chagas disease in the country, based on the available scientific evidence. The consensus is based on the articulation and strategic contribution of renowned Brazilian experts with knowledge and experience on various aspects of the disease. It is the result of a close collaboration between the Brazilian Society of Tropical Medicine and the Ministry of Health. It is hoped that this document will strengthen the development of integrated actions against Chagas disease in the country, focusing on epidemiology, management, comprehensive care (including families and communities), communication, information, education, and research

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707